Investigating mutations in blood cancers to improve treatment options
MPN-inducing mutations as biomarkers of synthetic lethality
This study is looking at blood cancers called myeloproliferative neoplasms (MPNs) to see how certain genetic changes can help doctors choose the best treatments and create new ones that target the cancer's root cause, with the hope of improving current therapies and helping patients stay in remission longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10849882 on NIH RePORTER |
What this research studies
This research focuses on myeloproliferative neoplasms (MPNs), which are blood cancers characterized by specific genetic mutations. The study aims to identify how these mutations can serve as biomarkers to guide treatment decisions and develop new therapies that target the cancer stem cells responsible for disease progression. By understanding the mechanisms of DNA repair in these cancer cells, the research seeks to enhance the effectiveness of existing treatments and potentially extend remission periods for patients. The approach involves analyzing genetic and epigenetic signatures to inform therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
Not a fit: Patients with other types of blood cancers or those without the specific mutations associated with MPNs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with myeloproliferative neoplasms, improving their chances of remission and overall survival.
How similar studies have performed: Previous research has shown promise in targeting genetic mutations in blood cancers, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Skorski, Tomasz — Temple Univ of the Commonwealth
- Study coordinator: Skorski, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.